A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 90
Healthy Volunteers: f
View:
• Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
• 20 years
• Patients requiring systemic chemotherapy with curative intent
• Written informed consent
Locations
Other Locations
Republic of Korea
Samsung Medical Center
RECRUITING
Seoul
Contact Information
Primary
Seok Jin Kim, MD, PhD
kstwoh@skku.edu
+82234101766
Time Frame
Start Date: 2017-03-01
Estimated Completion Date: 2026-12-28
Participants
Target number of participants: 600
Treatments
Lymphoma
Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
Related Therapeutic Areas
Sponsors
Leads: Samsung Medical Center
Collaborators: Samsung Genomic Institute